Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.6% – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL) shares dropped 4.6% during trading on Tuesday . The stock traded as low as $2.16 and last traded at $2.16. Approximately 234,556 shares were traded during trading, a decline of 78% from the average daily volume of 1,070,384 shares. The stock had previously closed at $2.26.

Analysts Set New Price Targets

A number of research firms have weighed in on AUTL. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Price Performance

The firm has a market cap of $578.75 million, a PE ratio of -1.80 and a beta of 2.05. The business’s fifty day moving average is $2.58 and its 200-day moving average is $3.50.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the company earned ($0.26) EPS. Analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the fourth quarter worth about $35,000. ProShare Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 2nd quarter valued at $43,000. Arkadios Wealth Advisors bought a new position in shares of Autolus Therapeutics in the fourth quarter worth $47,000. Capstone Investment Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the third quarter worth $51,000. Finally, Avanza Fonder AB bought a new stake in Autolus Therapeutics during the fourth quarter valued at $75,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.